Mode
Text Size
Log in / Sign up

Metabolic reprogramming of myeloid cells shapes spatial niches and immunometabolic landscapes in brain tumorsNew research explores how cell metabolism shapes brain tumor growth

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that myeloid cell metabolic programming shapes spatial niches and may offer future targets for immunotherapy.

This systematic review provides an overview of the immunometabolic landscape in brain tumors, specifically focusing on myeloid cells. The authors synthesize information regarding how interactions between different cell types and their respective metabolic programs shape spatial niches within the tumor microenvironment.

The review examines several factors influencing these environments, including the determinants of the immunometabolic landscape and the impact of tumor stage, type, and therapy on specific metabolic features. These findings suggest that myeloid cell metabolism is a key component in defining the local environment of brain tumors.

A primary limitation noted by the authors is that this is not a primary trial but a review of existing literature. Consequently, the results reflect theoretical and observed mechanisms rather than direct clinical trial outcomes. The evidence is currently insufficient to establish definitive clinical protocols.

For clinicians, the synthesis highlights potential opportunities for future research targeting specific metabolic states to improve cancer immunotherapy. While it does not provide immediate treatment changes, it identifies myeloid cell metabolism as a potential target for future therapeutic development in glioblastoma and other brain tumors.

How this fits prior evidence

This review addresses a gap by exploring the metabolic components of the tumor microenvironment. It complements existing evidence regarding the meningeal immune system as a target for glioblastoma immunotherapy and the role of the TOX/TCF-1 axis in cytotoxic failure. While prior coverage focused on systemic markers like platelet ratios or specific genetic drivers, this review focuses on the underlying immunometabolic landscape shaped by myeloid cell metabolism.

Living with a brain tumor like glioblastoma is incredibly hard. One reason it is so difficult to treat is that the tumor creates its own environment, often using nearby immune cells to help it grow and survive. This review looks closely at how these specific cells, called myeloid cells, change their metabolism to adapt to the tumor's surroundings.

By looking at existing research, scientists mapped out how different cell types interact with each other and with their metabolic programs. These interactions create specific spaces within the brain tumor that can influence how the cancer behaves. The review also looked at how things like the stage of the cancer or the type of treatment given might change these metabolic features.

It is important to note that this was a review of existing research rather than a new clinical trial on patients. While it does not provide immediate results for new treatments, it highlights specific ways we might target cell metabolism in the future to improve how immunotherapy works against brain cancer.

What this means for you:
Mapping how immune cells process energy helps identify new targets for treating glioblastoma tumors.

Common questions

What is a myeloid cell?

Myeloid cells are a type of immune cell found in the body. In this research, they were studied specifically because they are present in brain tumors like glioblastoma. The study looked at how these cells change their metabolism to survive and interact within the tumor's environment.

Does this mean a new treatment is available?

No, this was not a clinical trial for a new drug. It was a review of existing scientific literature. The goal was to map out how cell metabolism works in brain tumors to help scientists identify potential targets for future cancer immunotherapies.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Primary and recurrent brain tumors are aggressive malignancies with high mortality rates and limited treatment options. Glioblastoma (GBM) in particular are largely refractory to immunotherapies despite harboring a significant proportion of immune cells in the tumor microenvironment (TME). Increasing evidence suggests that the immunosuppressive TME in brain tumors is driven by functional and metabolic reprogramming of resident and infiltrating myeloid cells. Here, we examine the determinants of immunometabolic landscape in brain tumors and distinct features of heterogeneous myeloid cell populations. We discuss how interactions between cell types and metabolic programs shape spatial niches. We further dissect the effect of tumor stage, type and therapy in informing metabolic features of the TME. Collectively, this systematic review provides an overview of myeloid cell metabolism in brain tumors and highlights potential opportunities for future studies targeting metabolic states for cancer immunotherapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.